Skip to content

D&A at other companies

CorMedix logo
CorMedixCRMD
$10.54M+20,197%
Haemonetics logo
HaemoneticsHAE
$27.32M-3.2%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$112.9M+5.4%
ADMA Biologics logo
ADMA BiologicsADMA
$1.8M-5.3%
Paysign logo
PaysignPAYS
$2.64M+46.4%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's D&A?
Cerus (CERS) reported D&A of $447K in Q1 2026.
How has Cerus's D&A changed year-over-year?
Cerus's D&A increased by 45.6% year-over-year, from $307K to $447K.
What is the long-term trend for Cerus's D&A?
Over 4 years (2021 to 2025), Cerus's D&A has grown at a -18.0% compound annual growth rate (CAGR), from $3.15M to $1.43M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.